| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/01/2013 | CA2567961C Superloaded liposomes for drug delivery |
| 10/01/2013 | CA2563533C Compositions capable of facilitating penetration across a biological barrier |
| 10/01/2013 | CA2554883C Production and purification of recombinant arylsulfatase a |
| 10/01/2013 | CA2552241C Co-polymeric devices for controlled release of active agents |
| 10/01/2013 | CA2516520C N-acetylglucosaminyltransferase iii expression in lower eukaryotes |
| 10/01/2013 | CA2514510C Polymer conjugates of mutated neublastin |
| 10/01/2013 | CA2502304C Phenolic binding peptides |
| 10/01/2013 | CA2479835C An ephrin-b receptor protein involved in carcinoma |
| 10/01/2013 | CA2467689C Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase |
| 10/01/2013 | CA2451104C Electro-medical device for use with biologics |
| 10/01/2013 | CA2433862C Molecular antigen array presenting amyloid beta |
| 10/01/2013 | CA2418531C Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 10/01/2013 | CA2409643C Improvements in and relating to digestive/laxative compositions |
| 10/01/2013 | CA2353802C New protective antigen of group a streptococci |
| 10/01/2013 | CA2239448C Blockade of t lymphocyte down-regulation associated with ctla-4 signaling |
| 09/27/2013 | CA2784240A1 Stable bortezomib formulations |
| 09/26/2013 | WO2013142809A1 Baculovirus-based enterovirus 71 vlp as a vaccine |
| 09/26/2013 | WO2013142449A2 Treatment for chronic pain syndromes |
| 09/26/2013 | WO2013142374A1 Compositions and uses of antimicrobial materials with tissue-compatible properties |
| 09/26/2013 | WO2013142362A1 Regulator of complement activation and uses thereof |
| 09/26/2013 | WO2013142340A1 Devices and methods for preventing platelet activation |
| 09/26/2013 | WO2013142298A1 Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate |
| 09/26/2013 | WO2013142229A1 Designing novel peptides for inducing fibronectin matrix assembly |
| 09/26/2013 | WO2013142167A1 Gb virus c (hepatitis g virus) e2 glycoprotein as an immunomodulatory agent |
| 09/26/2013 | WO2013142135A1 Method of enhancing efficacy of blood transfusions |
| 09/26/2013 | WO2013142119A1 Silk reservoirs for drug delivery |
| 09/26/2013 | WO2013142088A1 Short antimicrobial lipopeptides |
| 09/26/2013 | WO2013141965A1 Tfpi inhibitors and methods of use |
| 09/26/2013 | WO2013141758A1 Pharmaceutical composition having neuroprotective, antiamnesic, antioxidant, antihypoxic, neurometabolic and anti-ischemic activity (variants) |
| 09/26/2013 | WO2013141750A1 Synthetic peptides wtih a non-narcotic type of analgesic effect |
| 09/26/2013 | WO2013141730A1 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections |
| 09/26/2013 | WO2013141519A1 Gingival extension device having periodontal tissue regeneration function |
| 09/26/2013 | WO2013141092A1 Cancer metastasis marker and method for diagnosing cancer metastasis using same |
| 09/26/2013 | WO2013140643A1 Carrier for intracellular delivery of functional protein |
| 09/26/2013 | WO2013140389A1 Plif multimeric peptides and uses thereof |
| 09/26/2013 | WO2013140388A1 Peptides for management of lactation |
| 09/26/2013 | WO2013140335A1 Hb-egf inhibitor derived from the r domain of diphtheria toxin for the treatment of diseases associated with the activation of the hb-egf/egfr pathway |
| 09/26/2013 | WO2013140104A1 Factor h for the use thereof as an antioxidant molecule |
| 09/26/2013 | WO2013140071A1 Cyclosporin a-based aqueous ophthalmic solution |
| 09/26/2013 | WO2013139906A1 Medicament for the treatment of acute myeloid leukemia (aml) |
| 09/26/2013 | WO2013139818A1 Lactoferrin for preventing or treating diarrhea |
| 09/26/2013 | WO2013139695A1 Compositions comprising a delivery agent and preparation thereof |
| 09/26/2013 | WO2013139694A1 Compositions of glp-1 peptides and preparation thereof |
| 09/26/2013 | WO2013139300A1 Recombinant lentiviral vector formulation |
| 09/26/2013 | WO2013138991A1 Lactoferrin supplementation and diarrhea |
| 09/26/2013 | WO2013138871A1 Immunomodulatory agent and uses therefor |
| 09/26/2013 | WO2013100822A3 Hemostimulating agent |
| 09/26/2013 | WO2013092672A3 Method for recombinant production of labyrinthopeptins and functional derivatives thereof |
| 09/26/2013 | WO2013074959A3 Enhanced staphylolytic activity of the staphylococcus aureus bacteriophage vb_saus-philpla88 virion-associated peptidoglycan hydrolase hydh5: fusions, deletions and synergy with lysh5 |
| 09/26/2013 | WO2013010708A3 Surfactant hair treatment agent comprising poly-l-lysine ii |
| 09/26/2013 | US20130253382 Targeted enzymatic degradation of quorum-sensing peptides |
| 09/26/2013 | US20130252907 Small Peptides And Methods For Blocking IgE Mediated Activation Of An Immune Cell |
| 09/26/2013 | US20130252902 Type a2 botulinum toxin preparation |
| 09/26/2013 | US20130252900 Microspheres useful for therapeutic vascular embolization |
| 09/26/2013 | US20130252899 Collagen hydrolysate for use to improve the health of human skin, hair and/or nails |
| 09/26/2013 | US20130252894 Sustained delivery of exenatide and other polypeptides |
| 09/26/2013 | US20130252890 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments |
| 09/26/2013 | US20130252889 Composition comprising vlp and amyloid beta peptide |
| 09/26/2013 | US20130252886 Methods of delaying and treating diabetes |
| 09/26/2013 | US20130252883 Macrocycles and Their Uses |
| 09/26/2013 | US20130252882 Antimicrobial 4-oxoquinolizines |
| 09/26/2013 | US20130252879 Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof |
| 09/26/2013 | US20130252876 Compositions and method for promoting musculoskeletal repair |
| 09/26/2013 | US20130252325 Duplexed Parvovirus Vectors |
| 09/26/2013 | US20130252306 Methods for increasing protein polyethylene glycol (peg) conjugation |
| 09/26/2013 | US20130251830 Therapeutic treatments using botulinum neurotoxin |
| 09/26/2013 | US20130251821 Vegf-activated fas ligands |
| 09/26/2013 | US20130251789 Tamper-resistant oral opioid agonist formulations |
| 09/26/2013 | US20130251786 Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| 09/26/2013 | US20130251781 Composition and Method for Treating Connective Tissue Damage |
| 09/26/2013 | US20130251762 Biomimetic scaffold for bone regeneration |
| 09/26/2013 | US20130251739 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 09/26/2013 | US20130251728 Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor |
| 09/26/2013 | US20130251727 Egfr-based peptides |
| 09/26/2013 | US20130251713 Methods for treating juvenile rhumatoid arthritis by administering a soluble ctla4 molecule |
| 09/26/2013 | US20130251701 Alkaline phosphatase to correct insulin resistance, hyperinsulinemia, and dyslipidemia |
| 09/26/2013 | US20130251689 Keratin compositions for treatment of bone deficiency or injury |
| 09/26/2013 | US20130251678 Bid dosage regimen for deb025 |
| 09/26/2013 | US20130251677 Genetic markers associated with interferon-alpha response |
| 09/26/2013 | US20130251675 Methods for Modulating Inflammatory Responses |
| 09/26/2013 | US20130251674 Non-Aqueous Single Phase Vehicles and Formulations Utilizing Such Vehicles |
| 09/26/2013 | US20130251672 Method and system to remove soluble tnfr1, tnfr2 and il2 in patients |
| 09/26/2013 | US20130251671 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| 09/26/2013 | US20130251669 Treatment of diabetes using g-csf and hyperbaric oxygen |
| 09/26/2013 | US20130251668 Use of osteoprotegerin (opg) to increase human pancreatic beta cell survival and proliferation |
| 09/26/2013 | US20130251651 Fetal Skin Cell Protein Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same |
| 09/26/2013 | US20130249131 Process for producing pellets for pharmaceutical compositions |
| 09/25/2013 | EP2641968A2 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and -d-galactosidase |
| 09/25/2013 | EP2641615A2 Compositions comprising dietary fat complexer and methods for their use |
| 09/25/2013 | EP2641614A1 Pharmaceutical preparation integrated with microneedles for skin treatment |
| 09/25/2013 | EP2641611A2 Combination therapy |
| 09/25/2013 | EP2641610A2 Anticancer composition containing gkn 1 |
| 09/25/2013 | EP2641609A1 Therapeutic agent for muscular dystrophy |
| 09/25/2013 | EP2641608A2 Products and methods using soy peptides to lower total and LDL cholesterol levels |
| 09/25/2013 | EP2641601A1 Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezimob |
| 09/25/2013 | EP2641600A1 Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies |
| 09/25/2013 | EP2641598A2 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof |
| 09/25/2013 | EP2640842A1 Methods and compositions for inducing an immune response to egfrviii |
| 09/25/2013 | EP2640417A2 Multivalent vaccine for filariasis |
| 09/25/2013 | EP2640413A1 A process for reduction and/or removal of fxi and fxia from solutions containing said coagulation factors |